“Adjuvanted Intranasal Norwalk Virus-Like Particle Vaccine Elicits Antibodies And Antibody-Secreting Cells That Express Homing Receptors For Mucosal And Peripheral Lymphoid Tissues.”. J Infect Dis 202 (11). J Infect Dis: 1649-58. doi:10.1086/657087.
. 2010. “B-Cell Responses To Intramuscular Administration Of A Bivalent Virus-Like Particle Human Norovirus Vaccine.”. Clin Vaccine Immunol 24 (5). Clin Vaccine Immunol. doi:10.1128/CVI.00571-16.
. 2017. “Dose-Dependent Neutralizing-Antibody Responses To Vaccinia.”. J Infect Dis 189 (3). J Infect Dis: 493-7. doi:10.1086/380906.
. 2004. “Dose-Related Safety And Immunogenicity Of A Trivalent Baculovirus-Expressed Influenza-Virus Hemagglutinin Vaccine In Elderly Adults.”. J Infect Dis 193 (9). J Infect Dis: 1223-8. doi:10.1086/503050.
. 2006. “Evaluation Of The Safety And Immunogenicity Of A Booster (Third) Dose Of Inactivated Subvirion H5N1 Influenza Vaccine In Humans.”. J Infect Dis 197 (4). J Infect Dis: 580-3. doi:10.1086/526537.
. 2008. “Immune Responses Of Healthy Subjects To A Single Dose Of Intramuscular Inactivated Influenza A/vietnam/1203/2004 (H5N1) Vaccine After Priming With An Antigenic Variant.”. J Infect Dis 198 (5). J Infect Dis: 635-41. doi:10.1086/590916.
. 2008. “Norovirus Vaccine Against Experimental Human Gii.4 Virus Illness: A Challenge Study In Healthy Adults.”. J Infect Dis 211 (6). J Infect Dis: 870-8. doi:10.1093/infdis/jiu497.
. 2015. “A Novel Intramuscular Bivalent Norovirus Virus-Like Particle Vaccine Candidate--Reactogenicity, Safety, And Immunogenicity In A Phase 1 Trial In Healthy Adults.”. J Infect Dis 210 (11). J Infect Dis: 1763-71. doi:10.1093/infdis/jiu337.
. 2014. “Safety And Immunogenicity Of A Subvirion Inactivated Influenza A/h5N1 Vaccine With Or Without Aluminum Hydroxide Among Healthy Elderly Adults.”. Vaccine 27 (37). Vaccine: 5091-5. doi:10.1016/j.vaccine.2009.06.057.
. 2009. “Safety And Immunogenicity Of An Inactivated Influenza A/h5N1 Vaccine Given With Or Without Aluminum Hydroxide To Healthy Adults: Results Of A Phase I-Ii Randomized Clinical Trial.”. J Infect Dis 198 (9). J Infect Dis: 1309-16. doi:10.1086/592172.
. 2008. “Safety And Immunogenicity Of An Inactivated Subvirion Influenza A (H5N1) Vaccine.”. N Engl J Med 354 (13). N Engl J Med: 1343-51. doi:10.1056/NEJMoa055778.
. 2006.